Reported about 10 hours ago
Novo Nordisk has stated that its acquisition proposal for U.S. drugmaker Metsera will not trigger any antitrust issues, despite a rival bid from Pfizer. The Danish firm, with a bid valued at $8.5 billion, is competing in the lucrative obesity drug market against Pfizer's $7.3 billion offer. Pfizer has filed a lawsuit against Novo, claiming it is breaching merger agreement obligations. However, Novo insists it complies with all restrictions. Both companies view the obesity sector as highly competitive, with Metsera's therapies projected to achieve significant sales.
Source: YAHOO